Abstract
The acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) inhibitory activities of a series of pyrano[2,3-b]quinolines (2, 3), [1,8]naphthyridines (5, 6), 4-amino-2,3-diaryl-5,6,7,8-tetrahydrofuro[2,3- b]quinolines (11-13) / 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]furo[2,3-b]pyridine (14), 4- amino-5,6,7,8-tetrahydro-2,3-diphenylthieno[2,3-b]quinoline (15) / 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl- 5H-cyclohepta[e]thieno[2,3-b]pyridine (16) are described. These compounds are tacrine analogues that have been prepared from readily available polyfunctionalized ethyl [6-amino-5-cyano-4H-pyran]-3-carboxylates (9, 10), ethyl [6-amino-5-cyanopyridine]-3-carboxylates (7, 8), 2-amino-3-cyano-4,5-diarylfurans (17-19) and 2- amino-3-cyano-4,5-diphenylthiophene (20) via Friedländer condensation with selected ketones. These compounds are competitive and, in a few cases, non-competitive inhibitors for AChE, the most potent being compound (14), though three-fold less active than tacrine. The BuChE inhibitory activity is only significant in compounds 11 and 14, ten-fold less active than tacrine. Furthermore, the products 12 and 13 are selective and moderate AChE inhibitors.
Keywords: tacrine analogues, buche inhibitors, pyrano[2,3-b]quinolines, naphthyridines, quinolines, pyridines
Mini-Reviews in Medicinal Chemistry
Title: Recent Developments in the Synthesis of Acetylcholinesterase Inhibitors
Volume: 3 Issue: 6
Author(s): Jose L. Marco and M. Carmo Carreiras
Affiliation:
Keywords: tacrine analogues, buche inhibitors, pyrano[2,3-b]quinolines, naphthyridines, quinolines, pyridines
Abstract: The acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) inhibitory activities of a series of pyrano[2,3-b]quinolines (2, 3), [1,8]naphthyridines (5, 6), 4-amino-2,3-diaryl-5,6,7,8-tetrahydrofuro[2,3- b]quinolines (11-13) / 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]furo[2,3-b]pyridine (14), 4- amino-5,6,7,8-tetrahydro-2,3-diphenylthieno[2,3-b]quinoline (15) / 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl- 5H-cyclohepta[e]thieno[2,3-b]pyridine (16) are described. These compounds are tacrine analogues that have been prepared from readily available polyfunctionalized ethyl [6-amino-5-cyano-4H-pyran]-3-carboxylates (9, 10), ethyl [6-amino-5-cyanopyridine]-3-carboxylates (7, 8), 2-amino-3-cyano-4,5-diarylfurans (17-19) and 2- amino-3-cyano-4,5-diphenylthiophene (20) via Friedländer condensation with selected ketones. These compounds are competitive and, in a few cases, non-competitive inhibitors for AChE, the most potent being compound (14), though three-fold less active than tacrine. The BuChE inhibitory activity is only significant in compounds 11 and 14, ten-fold less active than tacrine. Furthermore, the products 12 and 13 are selective and moderate AChE inhibitors.
Export Options
About this article
Cite this article as:
Marco L. Jose and Carreiras Carmo M., Recent Developments in the Synthesis of Acetylcholinesterase Inhibitors, Mini-Reviews in Medicinal Chemistry 2003; 3 (6) . https://dx.doi.org/10.2174/1389557033487908
DOI https://dx.doi.org/10.2174/1389557033487908 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Pharmacogenetics of the Antiplatelet Effect of Aspirin
Current Pharmaceutical Design Lipid Profile Results after Cardiovascular Prevention Programme: Euroaction Model in Spain
Endocrine, Metabolic & Immune Disorders - Drug Targets Resveratrol as a Supplemental Therapeutic in Cardiovascular and Metabolic Syndromes: A Critical Review
Current Nutrition & Food Science Drug-Drug Interactions Associated with Antiplatelet Therapy
Cardiovascular & Hematological Agents in Medicinal Chemistry Fullerenes for Cancer Diagnosis and Therapy: Preparation, Biological and Clinical Perspectives
Current Drug Metabolism Future Preventive and Therapeutic Targets for Transfusion-Related Acute Lung Injury
Current Pharmaceutical Design Neurological Aspects of Grief
CNS & Neurological Disorders - Drug Targets Pharmacological Activity of Cardiovascular Agents from Herbal Medicine
Cardiovascular & Hematological Agents in Medicinal Chemistry The Economic Costs for the Control of Cardiovascular Risk: An Overview
Current Pharmaceutical Design Drug Eluting Coronary Artery Stents
Current Drug Delivery The Role of Asymmetric Dimethylarginine (ADMA) in Endothelial Dysfunction and Cardiovascular Disease
Current Cardiology Reviews Characterization of Single Nucleotide Polymorphisms of Cytochrome P450 in an Australian Deceased Sample
Current Drug Metabolism Role of Sulfur Containing Amino Acids as an Adjuvant Therapy in the Prevention of Diabetes and its Associated Complications
Current Diabetes Reviews The Application of Mass Spectrometry to Proteomics and Metabolomics in Biomarker Discovery and Drug Development
Current Molecular Pharmacology The Ubiquitin Proteasome System as a Potential Target for the Treatment of Neurodegenerative Diseases
Current Pharmaceutical Design Sibutramine Effects on Central Mechanisms Regulating Energy Homeostasis
Current Neuropharmacology Prevention of Respiratory Syncytial Virus: A Review
Current Respiratory Medicine Reviews Natriuretic Peptides in Coronary Disease With Non-ST Elevation: New Tools Ready for Clinical Application?
Recent Patents on Cardiovascular Drug Discovery The Role of Uric Acid and Methyl Derivatives in the Prevention of Age-Related Neurodegenerative Disorders
Current Topics in Medicinal Chemistry Evaluation of Salivary Lipid Peroxidation End Product Level in Dental Caries
Infectious Disorders - Drug Targets